Antiretroviral Treatment 2014
|
|
- Elwin Lang
- 6 years ago
- Views:
Transcription
1 Activity Code FM285
2 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott
3 Learning Objectives Upon completion of this presentation, learners should be better able to: To review the most recent guidelines regarding when to start antiretroviral therapy To review the most recent guidelines regarding initial therapy of HIV infection To review the most recent guidelines regarding monitoring HIV-infected patients on antiretroviral therapy
4 Case Scenario # 1 55 yo white M with newly diagnosed HIV History of hypertension, depression Good adherence with medications (lisinopril, paroxetine). Smokes 1 ppd. Regular meals Exam: obese man. BP 130/80 CD4 count 550. HIV RNA 16,000 Estimated GFR 70. Lipids: TC 210. LDL 160 HLA-B5701 negative He says he s interested in treatment with a single-pill combination
5 Which regimen would you start? A. Dolutegravir + ABC/3TC B. Dolutegravir + TDF/FTC C. EFV/TDF/FTC D. RPV/TDF/FTC E. EVG/cobi/TDF/FTC F. DRV/r + TDF/FTC G. RAL + TDF/FTC 0% 0% 0% 0% 0% 0% 0% A. B. C. D. E. F. G. 10
6 Case Scenario # 2 55 yo African-American F with GERD, allergic rhinitis, newly diagnosed with HIV CD4 count 150, HIV RNA 250,000 Nurse. Irregular meal-times Medications: omeprazole, fluticasone Estimated GFR 60. HLA-B5701 negative She is interested in starting therapy
7 Which regimen would you start? A. Dolutegravir + ABC/3TC B. Dolutegravir + TDF/FTC C. EFV/TDF/FTC D. RPV/TDF/FTC E. EVG/cobi/TDF/FTC F. DRV/r + TDF/FTC G. RAL + TDF/FTC 0% 0% 0% 0% 0% 0% 0% A. B. C. D. E. F. G. 10
8 Updated: May 1, 2014
9 What s New in the Guidelines? New section on cost considerations: cost-sharing (co-pays), generic ART, targeted lab testing to reduce costs Change in recommendation re: frequency of CD4 count monitoring Change in classification of recommendations for initial therapy from Preferred to Recommended Regimens, and updated list of recommended regimens Addition of table that provides recommendations on ARV options when switching drugs because of adverse events
10 What s Not New in the DHHS Guidelines? HCV section not revised Check for the latest: This website is constantly being updated. Please remember to always refresh your page.
11 When to Start What to Start What to monitor
12 When to Start ART recommended for all HIV+ individuals. Strength of recommendation varies based on CD4 count: CD4 Cell Count < >500 Recommendation AI AII BIII AI: strong recommendation, data from randomized clinical trials AII: strong recommendation, non-randomized or observational cohort studies BIII: moderate recommendation, expert opinion Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at US DHHS Guidelines, January 2011.
13 When to Start Therapy Favors delayed ART Drug toxicities Risk of resistance if patient non-adherent Cost Favors early ART potency, simplicity, safety of current regimens transmission May prevent complications of untreated HIV: neurocognitive decline, CV disease, cancer Decreased HIV reservoirs Decreased immune activation, inflammation in blood and CSF Decreased neuronal injury Slide adapted from one by J. Eron, M.D. Jain et al, JID, 2013; Persaud D et al, CROI 2014, #75LB Peterson J et al, CROI 2014, #30 Peluso, CROI 2014, #31
14 Acute HIV and Elite Controllers Early HIV infection (acute or recent) Most acutely infected patients will reach CD4 threshold for ART initiation within short time (~ 1 yr) Early ART may lower VL set point, delay CD4 cell decline, and enhance CD4 recovery ART recommended although definitive evidence lacking Elite controllers ART recommended for controllers with declining CD4 counts or HIV-related complications My opinion: refer controllers to clinical trials, e.g. ACTG A5308 Hogan et al., JID, 2012; Le T, et al, NEJM, 2013; Lodi S, et al. CID, 2011; Grijsen et al, PLOS Medicine, March 2012; SPARTAC NEJM, January 17, 2013
15 What to Start 15
16 What to start DHHS guidelines Feb. 12, 2013 NNRTI + 2 NRTI PI + 2 NRTI INSTI + 2 NRTI Preferred regimens Efavirenz/tenofovir/emtricitabine Darunavir/ritonavir + tenofovir/emtricitabine Atazanavir/ritonavir + tenofovir/emtricitabine Raltegravir + tenofovir/emtricitabine
17 What to Start: Preferred Recommended Oxford English Dictionary: Prefer: Put in a privileged and more eminent position Recommend: Put forward... with approval as being suitable for a particular purpose or role The era of individualized therapy is here! 17
18 What to start DHHS guidelines NNRTI + 2 NRTI PI + 2 NRTI May 1, 2014 Recommended Regardless of VL, CD4 count Efavirenz/tenofovir/emtricitabine Darunavir/ritonavir + tenofovir/emtricitabine Atazanavir/ritonavir + tenofovir/emtricitabine Raltegravir + tenofovir/emtricitabine INSTI + 2 NRTI Elvitegravir/cobicistat/tenofovir/emtricitabine Dolutegravir + tenofovir/emtricitabine Dolutegravir + abacavir/lamivudine
19 Recommended but only for patients with pretherapy VL <100,000 NNRTI- Regimen What to start DHHS guidelines May 1, 2014 Rilpivirine/tenofovir/emtricitabine* Efavirenz + abacavir/lamivudine * PI Regimen Atazanavir/ritonavir + abacavir/lamivudine * Only if patient s CD4 count is >200
20 PI Regimens INSTI-Regimen Alternative Regimen Options Darunavir-ritonavir + abacavir/lamivudine Lopinavir-ritonavir + abacavir/lamivudine Lopinavir-ritonavir + tenofovir/emtricitabine Raltegravir + abacavir/lamivudine Effective and tolerable but have potential disadvantages or fewer data than Recommended Regimens.
21 Medications Removed from List of Options for Initial Therapy Zidovudine Nevirapine Ritonavir-boosted saquinavir Ritonavir-boosted fosamprenavir Unboosted atazanavir Maraviroc
22 Recent Trials of Initial ART EFV RPV EVG/cobi EFV EVG/cobi ATV/r DRV/r ATV/r DTG RAL DTG EFV DTG DRV/r RAL ATV/r
23 ECHO/ THRIVE Double-blind, double dummy RPV vs. EFV RPV + 2 NRTI* EFV + 2 NRTI* *ECHO: TDF/FTC; THRIVE: investigator selected NRTI RPV EFV Wk 96 VL <50 78% 78% More discontinuations due to AE in EFV gp Pts with pre-art VL >100 K, CD4<200: more virologic failures with RPV STaR Open label N=786 RPV/TDF/FTC SPC EFV/TDF/FTC SPC Wk 48 VL <50 86% 82% *SPC: single-pill combination RPV non-inferior to EFV overall and in pts with pre-art VL >100K; RPV superior to EFV in pts with pre-art VL 100K; more virologic failures and resistance in RPV gp as VL increases, esp. if VL >500K Cohen CJ et al, JAIDS, 2012; Cohen CJ et al, AIDS 2013; CJ Cohen, AIDS 2014
24 EVG/cobi vs. EFV or ATV/r + TDF/FTC Treatment-naïve patients. CrCL >70 ml/min Randomized, double blind, phase III trials Wk 96 VL <50 Study 102 (n = 700) EVG/cobi/TDF/FTC qd EFV/TDF/FTC qd 84% 82% Study 103 (n = 708) EVG/cobi/TDF/FTC qd ATV/r + TDF/FTC qd 83% 82% Sax P, et al. Lancet. 2012; DeJesus E, et al. Lancet. 2012; Zolopa A et al, JAIDS, 2013; Rockstroh J et al, JAIDS, 2013
25 EVG/cobi/TDF/FTC Advantages Well-tolerated: fewer CNS and rash events than with EFV Smaller increase in TC, LDL, HDL than with EFV Smaller increase in TGs than with ATV/r Disadvantages/considerations Cobi inhibits tubular secretion of Cr; early increase serum Cr (~0.14 mg/dl; typically < 0.4) Not recommended if CrCl <70 Cobicistat (CYP3A4 inhibitor) can affect metabolism of commonly used meds Separate from antacids (Mg, Al, Ca) by >2 hrs
26 DTG: Treatment Naïve Studies Wk 48 VL <50 SPRING-2 n=822 double blind DTG (qd) + 2 NRTI* RAL (bid) + 2 NRTI* *investigator selected ABC/3TC or TDF/FTC 88% 85% SINGLE n=833 double blind DTG + ABC/3TC EFV/TDF/FTC 88% 81% FLAMINGO n=484 open-label DTG + 2 NRTI* DRV/r + 2 NRTI* *investigator selected ABC/3TC or TDF/FTC Raffi F et al, Lancet, Walmsley S et al, NEJM, 2013; Walmsley S et al, CROI, 2014, 543. Clotet B et al. Lancet % 83%
27 DTG Trials in Treatment-naïve Patients: Summary DTG non-inferior to RAL DTG + ABC/3TC superior to EFV/TDF/FTC More treatment-related discontinuations in EFV/TDF/FTC group: 10% vs. 2% DTG superior to DRV/r Fewer withdrawals in the DTG group Baseline VL >100K: fewer virologic non-responders with DTG In pts receiving DTG for initial therapy, no treatment-emergent mutations detected DTG may have high genetic barrier to resistance Raffi F et al, Lancet, Raffi et al, IAS, Walmsley S et al, NEJM, 2013; Walmsley S et al, CROI, 2014, #543; Clotet B et al. Lancet 2014.
28 Comparing non-efv regimens: ACTG A5257 HIV+ adults, no previous ART (n=1809) Randomized 1:1:1. Open Label Therapy ATV/r + FTC/TDF RAL + FTC/TDF DRV/r + FTC/TDF At 96 wks, RAL superior to both PI/r regimens for combined tolerability and virologic efficacy; DRV/r superior to ATV/r Landovitz RL et al, CROI 2014, #85
29 Virologic Failure ATV/r: 13% RAL: 10% DRV/r: 15% ATV/r, RAL, DRV/r have equivalent virologic efficacy Landovitz RL et al, CROI 2014, #85
30 Tolerability Failure : ATV/r: 14% RAL: 1% DRV/r: 5% ATV/r was less well tolerated than DRV/r or RAL (mainly because of hyperbilirubinemia/jaundice) Lipids increased more in PI arm than in RAL arm; no difference between ATV/r and DRV/r arms Bone mineral density losses in spine and hip greater in PI arms than in RAL arm Landovitz RL et al, CROI 2014, #85; Ofotokun I et al, CROI 2014, #746; Brown T et al, CROI 2014, #779LB
31 Choosing an Antiretroviral Regimen: Two decisions Step 1: Decide which NRTI to use Step 2: Decide which drug to use within the NNRTI, PI or INSTI class
32 ABC/3TC TDF/FTC or ABC/3TC TDF/FTC NRTI PROS CONS TDF/FTC Single pill options available (with EFV, RPV, EVG/cobi) Active vs. HBV Lowers lipids ABC/3TC Not nephrotoxic When combined with DTG, superior to TDF/FTC/EFV Coformulation with DTG may be available this year Nephrotoxicity (particularly in those receiving other nephrotoxic agents, PIs) Increased loss of bone mineral density Must confirm HLA-B5701 negative VL >100 K: more virologic failures with ABC/3TC than TDF/FTC when used with ATV/r or EFV Some studies, but not all, show association with MI
33 Can we ditch Nucs? NEAT001? 805 pts randomized to DRV/r + TDF/FTC or DRV/r + RAL At wk 96, RAL non-inferior to TDF/FTC; however: Treatment-emergent resistance: 5/28 (RAL); 0/13 (TDF/FTC) Raffi et al, CROI 2014, # 84LB
34 Choosing 3 rd drug: NNRTI, PI, INSTI Factor Comorbidities Depression Dyslipidemia Bone disease HCV coinfected Acid lowering Rx CYP3A4-met. drug Considerations Avoid EFV* Favor RPV, DTG, EVG/cobi, RAL INSTI may be better than PI If considering use of simeprevir, favor RAL, DTG, RPV Avoid or caution with RPV, ATV/r Avoid PIs, cobi *In retrospective analysis, increased rate of suicidality in pts randomized to EFV regimens as compared to EFV-free regimens: 8 vs. 3.66/1000 PY. K Mollan et al, IDWeek, 2013
35 Drug Interactions: Exogenous Steroids Fluticasone 1 & budesonide 2 levels increased by PIs Cushing s syndrome, adrenal insufficiency reported Beclomethasone appears to be a safer alternative 3 1 DHHS guidelines for use of antiretroviral agents in HIV-1-infected adults and adolescents. May 1, Boyd S et al, JAIDS, 2013
36 Injectable Steroids in Patients on ART 170 HIV+ pts who received steroid injection 81 pts on PI ART 56 pts on non-pi ART 29 pts not on ART 4 pts: insufficient info 9 pts developed Cushings/adrenal insuff. No patient developed Cushings/adrenal insufficiency After steroid injection, 11% of patients on PI-containing ART developed clinical and lab evidence of Cushing s syndrome or secondary adrenal insufficiency Hyle E et al, JAIDS, 2013
37 What to Monitor 37
38 Monitoring after Starting ART Chemistries, BUN/Cr, LFTs: wk 2-8, then every 3-6 mo. CBC/diff: every 3-6 mo. Fasting glucose or HbA1c: every 3-6 mo. if previously abnormal; every 12 mo. if normal Lipids: if abnormal, every 6 mo; normal: every 12 mo. U/A every 12 months (every 6 mo. if on tenofovir) Tenofovir Fanconi s syndrome: glucosuria, proteinuria ( 1+), urinary phosphate wasting Cobicistat, dolutegravir inhibit creatinine secretion serum Cr without affecting renal function If >0.4 mg/dl increase in Cr on cobi check for TDF toxicity DHHS guidelines, ; Aberg J et al, CID, 2013
39 Clinical Scenario Before ART After initiating ART After modifying ART in pt with suppressed VL Viral Load Monitoring At entry into care If ART initiation deferred, repeat before initiating ART In patients not initiating ART, repeat testing optional Within 2 to 4 wks; thereafter every 4 to 8 wks until VL suppressed. 4 to 8 wks after modifying ART CD4 Count Monitoring At entry into care If ART deferred, every 3 to 6 mo. 3 mo. after initiation of ART Monitor according to CD4 count and ART duration
40 Clinical Scenario VL Monitoring CD4 Monitoring First 2 yrs of ART Every 3 to 4 mo. Every 3 to 6 mo. After 2 yrs of ART, VL suppressed, CD After 2 yrs of ART, VL suppressed, CD4 >500 Change in clinical status, e.g. new HIV clinical sx or drug that may affect CD4 count Can extend to every 6 mo. Every 3 mo. Every 12 mo Optional Perform CD4 count, repeat as clinically indicated Monitoring of lymphocyte subsets other than CD4 (e.g. CD8, CD19) NOT routinely recommended
41 CD4 Count Monitoring Patients with VL <200 & CD4 count >300: 99% likelihood CD4 count will stay >200 1 Substantial cost savings with less frequent CD4 cell monitoring 2 1 Gale, CID, 2013; 2 Hyle E et al, JAMA, 2013;
42 Case Scenario # 1 55 yo white M with newly diagnosed HIV Salient considerations: High risk for cardiovascular disease (HTN, smoking) 2013 AHA risk calculator: 10 yr ASCVD risk is 13% Low VL (16,000), high CD4 count (550) Estimated CrCl 70 Borderline lipids Regular meals Prefers single-pill combination
43 Which regimen would you start? 1. Dolutegravir + ABC/3TC 2. Dolutegravir + TDF/FTC 3. EFV/TDF/FTC 4. RPV/TDF/FTC 5. EVG/cobi/TDF/FTC 6. DRV/r + TDF/FTC 7. RAL + TDF/FTC
44 Case Scenario # 2 55 yo F with newly diagnosed HIV Salient considerations GERD, requiring proton-pump inhibitor Allergic rhinitis, on nasal fluticasone Low CD4 count (150), high VL (250,000) Irregular meal-times (nurse) Estimated GFR 60 HLA-B5701 negative
45 Which regimen would you start? 1. Dolutegravir + ABC/3TC 2. Dolutegravir + TDF/FTC 3. EFV/TDF/FTC 4. RPV/TDF/FTC 5. EVG/cobi/TDF/FTC 6. DRV/r + TDF/FTC 7. RAL + TDF/FTC
46 Activity Code FM285
Antiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationInitial Approach to the Patient Newly Diagnosed with HIV
Activity Code TM809 Initial Approach to the Patient Newly Diagnosed with HIV Rajesh T. Gandhi, M.D. Massachusetts General Hospital Disclosures: grant support from Tibotec (now Janssen), Abbott and Viiv
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationSingle Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era
Activity Code FM285 Single Pill Combinations Versus Generics: Prescribing Practices in a New Healthcare Era Monica Gandhi MD, MPH Clinic Director, Ward 86 HIV Clinic, SFGH/UCSF Learning Objectives Upon
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More informationApproach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Initial Therapy for Antiretroviral Naïve HIV Infected Patients Michelle Cespedes, MD, MS Associate Professor of Medicine Division of Infectious Disease Icahn School of Medicine at Mount Sinai Disclosures
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More information1/13/16. Updated April 2015
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP Assistant Professor UNM College of Pharmacy bjakeman@salud.unm.edu Pharmacist objectives: 1. Summarize key updates to the DHHS treatment guidelines. 2. Identify
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationAntiretroviral Therapy: When and What to Start. Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine
Antiretroviral Therapy: When and What to Start Joe Eron, MD University of North Carolina at Chapel Hill School of Medicine Learning Objectives As a results of participating in this activity participants
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationHIV: Approach to the Treatment-Naïve Patient
HIV: Approach to the Treatment-Naïve Patient Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Approach
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationBHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes
BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationWhat to look for in a paper?
What to look for in a paper? D Costagliola Institut Pierre Louis d épidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, INSERM Disclosures I have received consultancy fees, honoraria,
More informationThe BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir
The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir A Pilot Study of the Novel Antiretroviral Combination of Atazanavir and Raltegravir in HIV-1 Infected Subjects with Virologic Suppression
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationCases: Treatment of Hepatitis C in HIV/HCV Coinfection
Cases: Treatment of Hepatitis C in HIV/HCV Coinfection David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationHIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
More informationTUESDAY AM HIV DISCUSSION SERIES. 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D.
TUESDAY AM HIV DISCUSSION SERIES 8/25/2015 Management of Treatment-Naïve Patients Ellen Kitchell, M.D. HAART Initiation/HIV Treatment for Antiretroviral-Naïve Patients Ellen Kitchell, M.D. The Art of HAART
More informationSlide #1 Case Presentation: Kidney Disease
Slide #1 Case Presentation: Kidney Disease Christina Wyatt, MD Mount Sinai, New York Slide #2 Disclosures Investigator-initiated research support Gilead Sciences Honoraria for internal education Bristol
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationDidactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012
Didactic Series Update: 2012 HIV Treatment Guidelines Daniel Lee, MD August 30, 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationHighlights of AIDS 2012 CCO Official Conference Coverage of the XIX International AIDS Conference
Highlights of AIDS 2012 CCO Official Conference Coverage of the XIX International AIDS Conference July 22-27, 2012 Washington, DC Sylvia Ojoo, MRCP UK Clinical Assistant Professor of Medicine University
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More information